v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
COSTS AND EXPENSES:        
Research and development $ 2,703,831 $ 1,995,571 $ 6,821,775 $ 5,798,526
General and administrative 1,260,048 1,091,921 3,972,275 3,647,412
Total costs and expenses 3,963,879 3,087,492 10,794,050 9,445,938
LOSS FROM OPERATIONS (3,963,879) (3,087,492) (10,794,050) (9,445,938)
OTHER INCOME:        
Gain on revaluation of derivative warrants 46,000 66,000 43,000 19,050
Interest income, net 14,072 6,558 38,041 15,440
Total other income, net 60,072 72,558 81,041 34,490
NET LOSS (3,903,807) (3,014,934) (10,713,009) (9,411,448)
DEEMED DIVIDEND ON PREFERRED STOCK   (2,241,795)   (2,241,795)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (3,903,807) $ (5,256,729) $ (10,713,009) $ (11,653,243)
BASIC AND DILUTED NET LOSS PER COMMON SHARE $ (0.42) $ (1.65) $ (1.51) $ (5.29)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 9,386,703 3,184,856 7,098,285 2,204,554

Source